Objective: To observe the clinical effect and prognosis of Acarbose in the treatment of stable angina pectoris combined impaired glucose tolerance. Methods: 128 patients with stable angina pectoris in patients with impaired glucose tolerance were randomly divided into combined Acarbose treatment group (treatment group) and the conventional treatment group (control group), 64 patients in each group. After treatment of 3-4 years, the efficacy was observed. Results: The clinical improvement of angina treatment group was 87.5％; the control group was 71.8％. The treatment group during treatment,there were 11 cases of unstable angina (17.1％), myocardial infarction 10 cases (15.6％), heart failure 2 cases (3.0％), sudden cardiac death 1 case (1.5％), diabetes 2 cases (3.0％), while the control group had 18 cases with unstable angina (28.1％), myocardial infarction 20 cases (31.2％), heart failure 6 cases (9.3％), 4 cases of sudden cardiac death (6.2％), diabetes 8 cases (12.5％). The treatment group significantly improved symptoms of angina, unstable angina, myocardial infarction, heart failure, sudden cardiac death and the incidence of diabetes were significantly lower than those of the control group (P＜0.05). Conclusion: Acarbose in the treatment of the stable angina combined impaired glucose tolerance can significantly improve the prognosis, reduce the incidence of cardiovascular events and diabetes rates.%目的:观察阿卡波糖治疗稳定性心绞痛合并糖耐量异常对临床及预后的影响.方法:将128例稳定性心绞痛合并糖耐量异常患者随机分为阿卡波糖治疗组(治疗组)和常规治疗组(对照组),每组各64例.治疗3～4年.结果:两组患者心绞痛的临床改善情况,治疗组总有效率为87.5%,对照组总有效率为71.8%.治疗组在治疗过程中,共发生不稳定性心绞痛11例(17.1%),心肌梗死10例(15.6%),心力衰竭2例(3.0%),心源性猝死1例(1.5%),糖尿病2例(3.0%),而对照组发生不稳定性心绞痛18例(28.1%),心肌梗死20例(31.2%),心力衰竭6例(9.3%),心源性猝死4例(6.2%),糖尿病8例(12.5%).治疗组可明显改善心绞痛症状,不稳定性心绞痛、心肌梗死、心力衰竭、心源性猝死和糖尿病的发生率低于对照组(P<0.05).结论:阿卡波糖治疗稳定性心绞痛合并糖耐量异常可显著改善预后,降低心血管事件和糖尿病的发生率.
展开▼
